FDA approves acellular tissue engineered vessel as conduit for extremity arterial injuries

admin
1 Min Read

Symvess, a sterile, cell-free tissue engineered vessel made of human extracellular matrix proteins, has been approved by the FDA as a vascular conduit for extremity arterial injuries in adults. In a study of 54 patients, 67% retained primary patency and 72% retained secondary patency after treatment with Symvess. The product received priority review and regenerative medicine advanced therapy designation. Symvess is designed as a priority product by the U.S. Department of Defense to address the significant unmet medical need for vascular trauma treatment. The approval of Symvess provides an important treatment option using advanced tissue engineering technology.

Source link

Share This Article
error: Content is protected !!